|
|
Factsheet as on May 31, 2025 |
Factsheet as on May 31, 2025
Structure
Open Ended
Fund Category
Thematic/Sectoral
Fund Manager
Chirag Dagli
Exit Load
Within 1 Month - 0.5%
Fund Size
Rs 2961 crs
Launch Date
November 30, 2018
Investment Objective
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.
Market Cap Allocation
Scheme Performance
| 1 Year | 2 Years | 3 Years | 5 Years | |
| Scheme (%) | 18.67 | 30.64 | 23.29 | 23.68 |
| Nifty 500 (%) | 8.07 | 20.26 | 17.32 | 23.83 |
Top 10 Holdings
| Company Name | % of Assets |
| Cipla Ltd. | 8.9 |
| Cohance Lifesciences Ltd. | 8.8 |
| Sun Pharmaceutical Industries Ltd. | 8.7 |
| IPCA Laboratories Ltd. | 8.2 |
| Gland Pharma Ltd. | 4.9 |
| Alembic Pharmaceuticals Ltd. | 4.9 |
| Globus Medical Inc | 4.6 |
| Laurus Labs Ltd. | 4.6 |
| Apollo Hospitals Enterprise Ltd. | 4.5 |
| Sai Life Sciences Ltd. | 4.1 |
Year On Year Performance (Scheme V/S Nifty 500)
Ratios:
| Standard Deviation | 15.13 |
| Beta | 0.75 |
| Information Ratio | 0.13 |
| Sharpe Ratio | 0.29 |
Top 10 Sectoral Holdings (%)
SIP Returns
Source: MFI Explorer, Bloomberg.
Please refer to the disclaimer and glossaries
Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390
Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390